10x Genomics Inc. (TXG)
10x Genomics Statistics
Share Statistics
10x Genomics has 122.3M shares outstanding. The number of shares has increased by 1.58% in one year.
| Shares Outstanding | 122.3M |
| Shares Change (YoY) | 1.58% |
| Shares Change (QoQ) | 0.47% |
| Owned by Institutions (%) | 87.06% |
| Shares Floating | 113.88M |
| Failed to Deliver (FTD) Shares | 2.61K |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 7.61M, so 6.32% of the outstanding shares have been sold short.
| Short Interest | 7.61M |
| Short % of Shares Out | 6.32% |
| Short % of Float | 6.75% |
| Short Ratio (days to cover) | 4.26 |
Valuation Ratios
The PE ratio is -9.47 and the forward PE ratio is -24.61. 10x Genomics's PEG ratio is 0.31.
| PE Ratio | -9.47 |
| Forward PE | -24.61 |
| PS Ratio | 2.83 |
| Forward PS | 1.4 |
| PB Ratio | 2.44 |
| P/FCF Ratio | -301.92 |
| PEG Ratio | 0.31 |
Enterprise Valuation
10x Genomics Inc. has an Enterprise Value (EV) of 6.29B.
| EV / Earnings | -34.46 |
| EV / Sales | 10.3 |
| EV / EBITDA | -46.96 |
| EV / EBIT | -32.34 |
| EV / FCF | -1098.38 |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.97 |
| Quick Ratio | 4.26 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 10.42 |
| Cash Flow / Debt | 0.08 |
| Interest Coverage | -48639.75 |
Financial Efficiency
Return on equity (ROE) is -0.26% and return on capital (ROIC) is -25.22%.
| Return on Equity (ROE) | -0.26% |
| Return on Assets (ROA) | -0.2% |
| Return on Capital (ROIC) | -25.22% |
| Revenue Per Employee | $467,676.11 |
| Profits Per Employee | $-139,836.91 |
| Employee Count | 1,306 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.36 |
Taxes
| Income Tax | 4.93M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -74.9% in the last 52 weeks. The beta is 1.93, so 10x Genomics's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | -74.9% |
| 50-Day Moving Average | 12.29 |
| 200-Day Moving Average | 16.77 |
| Relative Strength Index (RSI) | 35.36 |
| Average Volume (20 Days) | 2.79M |
Income Statement
In the last 12 months, 10x Genomics had revenue of 610.78M and earned -182.63M in profits. Earnings per share was -1.52.
| Revenue | 610.78M |
| Gross Profit | 414.48M |
| Operating Income | -194.56M |
| Net Income | -182.63M |
| EBITDA | -133.99M |
| EBIT | -194.56M |
| Earnings Per Share (EPS) | -1.52 |
Balance Sheet
The company has 344.07M in cash and 82.61M in debt, giving a net cash position of 261.45M.
| Cash & Cash Equivalents | 344.07M |
| Total Debt | 82.61M |
| Net Cash | 261.45M |
| Retained Earnings | -1.47B |
| Total Assets | 918.64M |
| Working Capital | 466.75M |
Cash Flow
In the last 12 months, operating cash flow was 6.66M and capital expenditures -12.39M, giving a free cash flow of -5.73M.
| Operating Cash Flow | 6.66M |
| Capital Expenditures | -12.39M |
| Free Cash Flow | -5.73M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 67.86%, with operating and profit margins of -31.85% and -29.9%.
| Gross Margin | 67.86% |
| Operating Margin | -31.85% |
| Pretax Margin | -29.09% |
| Profit Margin | -29.9% |
| EBITDA Margin | -21.94% |
| EBIT Margin | -31.85% |
| FCF Margin | -0.94% |
Dividends & Yields
TXG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.14% |
| FCF Yield | -0.5% |
Analyst Forecast
The average price target for TXG is $18, which is 91.1% higher than the current price. The consensus rating is "Hold".
| Price Target | $18 |
| Price Target Difference | 91.1% |
| Analyst Consensus | Hold |
| Analyst Count | 16 |
Stock Splits
The last stock split was on Jul 17, 2006. It was a backward split with a ratio of 1:2.
| Last Split Date | Jul 17, 2006 |
| Split Type | backward |
| Split Ratio | 1:2 |
Scores
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 6 |